AstraZeneca announced the initiation of two new phase III clinical trials investigating the potential of their fixed-dose triple combination inhaled therapy to address cardiopulmonary risk and improve outcomes in people living with COPD.
THARROS is the first-ever prospective phase III trial investigating the potential effect of our triple therapy on severe cardiopulmonary outcomes in people with COPD who also have elevated cardiopulmonary risk, irrespective of exacerbation history. If positive, THARROS will provide critical evidence that could advance treatment goals in COPD.
ATHLOS is another new phase III trial investigating our triple therapy vs inhaled corticosteroid/long-acting β2-agonist budesonide/formoterol fumarate or placebo on cardiopulmonary parameters including hyperinflation and exercise endurance time, which are associated with health status and survival.
These trials support AstraZeneca's ambition to transform care for people with COPD by expanding the scientific understanding of COPD, its connection to cardiopulmonary risk, and the potential impact of triple therapy on outcomes. To learn more about these trials, please view the press release. You can also find the clinicaltrials.gov links for both trials (which are actively recruiting) below for you to list on your website as you see fit:
THARROS »
ATHLOS »